LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Cognetix explored the use of snail toxins for the treatment of epilepsy, pain and anesthesia.
Cognetix
Salt Lake City, UT
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.